DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, today announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The INSPIREa study will investigate if Stimuvax can extend overall survival in Asian patients with unresectable stage III NSCLC.
